Search

Objective: Liver transplantation requires lifelong immunosuppression, which has significant psychological and physiological implications. While depression and anxiety are prevalent among transplant recipients, their potential relationship with immune tolerance remains unclear. This study aims to evaluate the association between depression, anxiety, and immune tolerance in liver transplant recipients., Methods: This cross-sectional study included 179 adult liver transplant recipients, categorized as tolerant (n=49) and non-tolerant (n=130) based on immunosuppressive status. Depression and anxiety levels were assessed using the Beck Depression Inventory (BDI-II) and Spielberger's State-Trait Anxiety Inventory (STAI-Y). Data were analyzed using appropriate statistical tests, with significance set at P<0.05., Results: A history of psychiatric disorders, including depression and anxiety, was observed in 19.0% and 53.1% of participants, respectively. No significant differences were found in BDI-II scores between tolerant (13.14±10.67) and non-tolerant (12.45±11.38) groups. Similarly, STAI-Y State and Trait anxiety scores did not differ significantly between groups (P=0.23 for both)., Conclusions: While depression and anxiety are common in liver transplant recipients, this study did not find a significant association with immune tolerance. Given the cross-sectional design and sample size limitations, further longitudinal research is needed to determine whether psychological factors influence transplant outcomes., Competing Interests: Source of Funding and Conflicts of Interest: This study was funded by the Shiraz University of Medical Sciences, Shiraz, Iran. The authors declare no conflict of interest regarding the publication of this manuscript., (Copyright © 2025 Society for Biopsychosocial Science and Medicine.)

Background: In this study, we report the epidemiology of COVID-19 among recipients of organ transplantation and evaluate associated factors with death., Methods: We screened 6969 patients who had organ transplantations in our center for COVID-19. Specific data on presentation, clinical course, treatment, and prognosis were acquired., Results: We found 85 patients (66 liver, 16 kidney, 2 kidney-pancreas, and 1 liver-kidney recipient) who acquired COVID-19. Most common symptoms included fever (48.2%), cough (41.2%), myalgia (41.2%), and fatigue (40%). Dyspnea developed in 33% of patients. Overall, one-third of patients had an oxygen saturation of below 90% on admission. Patients were hospitalized for a median (interquartile range) of 9 (5, 13.7) days and had a 33.9% intensive care unit admission rate. Overall, 17 patients (20%) died, which included 31.3% of patients with kidney transplantations and 18.2% of patients with liver transplantations. All 4 pediatric patients in our series died. In our univariate analysis among adults, rates of leukopenia (38.4% versus 13.2%; P = 0.04), low albumin levels (53.8% versus 10.2%; P = 0.001), and shorter duration between transplantation and COVID-19 (P = 0.02), were higher among patients who died. In our least absolute shrinkage and selection operator regression model, low albumin levels (OR, 4.48; 95% confidence interval, 1.16-17.27) were associated with higher risk of death., Conclusions: This is the largest single-center report on abdominal transplantations and COVID-19. Liver and kidney transplant recipients have an increased risk of mortality compared with the general population due to COVID-19. More specifically, pediatric patients and those with low albumin levels are at higher risks of death due COVID-19., Competing Interests: The authors declare no funding or conflicts of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)

Aim: Portal vein thrombosis (PVT) is a common complication amongst patients with liver cirrhosis. The PVT risk factors and its impact on post liver transplant outcome has not been well defined, yet. This study aimed to investigate PVT prevalence, its risk factors and influence on early and long-term outcomes after liver transplantation., Methods: Adult (>18 years) patients with liver cirrhosis undergoing liver transplantation between March 2013 to March 2015 were included. Presence or absence of PVT was recorded at transplant. PVT risk factors in patients with liver cirrhosis and its impact on early and long-term outcomes were analysed., Results: Portal vein thrombosis was diagnosed in 174 patients (17.3%). Large oesophageal varices (grade II and III vs grade I) (OR: 2.5; 95% CI: 1.46-4.26; P = 0.001), diabetes mellitus before transplantation (OR: 2.03; 95% CI: 1.13-3.64; P = 0.017) and cryptogenic-NASH (OR: 1.36; 95% CI: 1.08-1.72; P = 0.008) as a cause of underlying liver disease were the independent risk factors for PVT. PVT (OR: 2.05; 95% CI: 1.10-3.81; P = 0.023) was an independent predictor of early (within 90 days) posttransplant mortality, but did not influence long-term survival., Conclusion: Portal vein thrombosis prevalence is high in pretransplant period. NASH related cirrhosis and diabetes mellitus might be risk factors for PVT. More intense screening of these patients for PVT is warranted., (© 2018 John Wiley & Sons Ltd.)